Asian Spectator


The Times

.

Oral semaglutide demonstrated cardiovascular safety in people ...

  • Written by LATEST ASIANET NEWS RELEASES
  • Published in Asia Net
SAN FRANCISCO, June 12, 2019 /PRNewswire-AsiaNet / -- Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. T...

Authors: LATEST ASIANET NEWS RELEASES

Read more

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-libraryskorbettelegram webpashagaming girişcasibomjojobettelegram ifşadeneme bonusubetwoonagen bolatelegram下载jojobetjojobetGrandpashabetngsbahisholiganbetmadridbetjojobetcasibom